Lack of data from the US Food and Drug Administration (FDA) Adverse Event System makes analyses of the risks of newly approved anti-Alzheimer's antibodies inadequate to determine whether such risks justify the minimal clinical benefits reported. A recent disproportionate analysis in the Journal of Alzheimer's Disease by Ge et al. is a case in point. Among serious adverse effects, it only addresses amyloid associated imaging abnormalities, whereas the even more threatening ones, brain tissue loss and therapy-related death, are not mentioned. We urge the FDA to prioritize monitoring of all adverse effects and encourage transparency from the drug manufacturers.
GeWYanYHuY, et al.Unveiling the safety profile of lecanemab: a comprehensive analysis of adverse events using FDA Adverse Event Reporting System Data. J Alzheimers Dis.Epub ahead of print 12 January 2025. DOI: 13872877241307246.
2.
van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2023; 388: 9–21.
3.
Høilund-CarlsenPFRevheimMECostaT, et al.Passive Alzheimer's immunotherapy: a promising or uncertain option?Ageing Res Rev2023; 90: 101996.
4.
GiacobiniECuelloACFisherA. Reimagining cholinergic therapy for Alzheimer’s disease. Brain2022; 145: 2250–2275.
5.
XuHGarcia-PtacekSJönssonL, et al.Long-term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology2021; 96: e2220–e2230.
6.
Høilund-CarlsenPFAlaviACastellaniRJ, et al.Alzheimer's amyloid hypothesis and antibody therapy: melting glaciers?Int J Mol Sci2024; 25: 3892.
7.
AlvesFKalinowskiPAytonS. Accelerated brain volume loss caused by anti-β-amyloid drugs: a systematic review and meta-analysis. Neurology2023; 100: e2114–e2124.
SwansonCJZhangYDhaddaS, et al.A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-aβ protofibril antibody. Alzheimers Res Ther2021; 13: 80.
10.
LenzerJBrownleeS. Donanemab: conflicts of interest found in FDA committee that approved new Alzheimer's drug. BMJ2024; 386: q2010.
